Background: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly understood. Understanding patient perspectives on these phenomena is important to identify unmet needs, which can be used to improve (es)ketamine treatments. Aims: To explore the perspectives of TRD patients participating in “off label” oral esketamine treatment. Materials and methods: In-depth interviews were conducted with 17 patients (11 women) after a six-week, twice-weekly esketamine treatment program, and subsequently after six months of at-home...
Background: Treatment-resistant Depression (TRD) represents a widespread disorder with significant d...
Background: Treatment-resistant Depression (TRD) represents a widespread disorder with significant d...
Over the last few years, ketamine has been studied as a possible treatment option for Major Depressi...
Background: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-...
Background: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-...
Background Ketamine is a new and promising treatment for depression but comes with challenges to im...
BACKGROUND: Intravenous infusion of ketamine can produce rapid and large symptom reduction in patien...
INTRODUCTION: Ketamine and its S-enantiomer esketamine are novel pharmacotherapeutic options for tre...
Background: Off-label ketamine treatment has shown acute antidepressant effects that offer hope for ...
BACKGROUND: There is an urgent need to develop additional treatment strategies for patients with tre...
Background Ketamine has recently received considerable attention regarding its antidepressant and ...
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esket...
Treatments such as ketamine psychotherapy face substantial financial and regulatory obstacles to dis...
Background: Treatment-resistant Depression (TRD) represents a widespread disorder with significant d...
Background: Treatment-resistant Depression (TRD) represents a widespread disorder with significant d...
Over the last few years, ketamine has been studied as a possible treatment option for Major Depressi...
Background: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-...
Background: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-...
Background Ketamine is a new and promising treatment for depression but comes with challenges to im...
BACKGROUND: Intravenous infusion of ketamine can produce rapid and large symptom reduction in patien...
INTRODUCTION: Ketamine and its S-enantiomer esketamine are novel pharmacotherapeutic options for tre...
Background: Off-label ketamine treatment has shown acute antidepressant effects that offer hope for ...
BACKGROUND: There is an urgent need to develop additional treatment strategies for patients with tre...
Background Ketamine has recently received considerable attention regarding its antidepressant and ...
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esket...
Treatments such as ketamine psychotherapy face substantial financial and regulatory obstacles to dis...
Background: Treatment-resistant Depression (TRD) represents a widespread disorder with significant d...
Background: Treatment-resistant Depression (TRD) represents a widespread disorder with significant d...
Over the last few years, ketamine has been studied as a possible treatment option for Major Depressi...